Reviva Pharmaceuticals Granted USPTO Patent for Brilaroxazine

The U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent 12053477 to Reviva Pharmaceuticals Holdings, a late-stage pharmaceutical company that develops therapies to address unmet medical needs in the areas of central nervous system (CNS), inflammatory, and cardiometabolic diseases. This patent expands the company's existing patent protection in key market Japan and covers the use of brilaroxazine for the treatment of idiopathic pulmonary fibrosis (IPF) and for the treatment of pulmonary fibrosis in subjects with chronic obstructive pulmonary disease (COPD), sickle cell anaemia, scleroderma, or lung cancer. The U.S. Food and Drug Administration (FDA) has designated brinalozazine as an Orphan Drug for the treatment of IPF.

Laxminarayan Bhat, Ph.D., Founder, President, and CEO, stated, "We are happy to further expand our intellectual property (IP) for brilaroxazine which we believe has the broad therapeutic potential to treat inflammatory conditions like IPF driven by underlying disruption in serotonin signalling." "This additional patent is intended to optimise the value of brilaroxazine for the treatment of interstitial lung diseases and builds on our existing IP in pulmonary hypertension."